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Abstract
Background: Epilepsy patients have distinct immune/inflammatory cell profiles and inflammatory mediator levels
in the blood. Although the neural origin of inflammatory cells and mediators has been implied, few studies have
measured these inflammatory components in the human brain itself. This study examines the brain levels of
chemokines (8), cytokines (14), and vascular injury mediators (3) suspected of being altered in epilepsy.
Methods: Soluble protein extracts of fresh frozen resected hippocampus, entorhinal cortex, and temporal cortex
from 58 medically refractory mesial temporal lobe epilepsy subjects and 4 nonepileptic neurosurgical subjects
were assayed for 25 inflammation-related mediators using ultrasensitive low-density arrays.
Results: Brain mediator levels were compared between regions and between epileptic and nonepileptic cases,
showing a number of regional and possible epilepsy-associated differences. Eotaxin, interferon-γ, interleukin (IL)-2,
IL-4, IL-12 p70, IL-17A, tumor necrosis factor-α, and intercellular adhesion molecule (ICAM)-1 levels were highest
in the hippocampus, the presumptive site of epileptogenesis. Surprisingly, IL-1β and IL-1α were lowest in the
hippocampus, compared to cortical regions. In the temporal cortex, IL-1β, IL-8, and MIP-1α levels were highest,
compared to the entorhinal cortex and the hippocampus.
The most pronounced epilepsy-associated differences were decreased levels of eotaxin, IL-1β, C-reactive protein,
and vascular cell adhesion molecule (VCAM)-1 and increased IL-12 p70 levels. Caution must be used in interpreting
these results, however, because nonepileptic subjects were emergent neurosurgical cases, not a control group.
Correlation analyses of each mediator in each brain region yielded valuable insights into the regulation of these
mediator levels in the brain. Over 70 % of the associations identified were between different mediators in a single
brain region, providing support for local control of mediator levels. Correlations of different mediators in different
brain regions suggested more distributed control mechanisms, particularly in the hippocampus. Interestingly, only
four mediators showed robust correlations between the brain regions, yet levels in three of these were significantly
different between regions, indicating both global and local controls for these mediators.
Conclusions: Both brain region-specific and epilepsy-associated changes in inflammation-related mediators
were detected. Correlations in mediator levels within and between brain regions indicated local and global
regulation, respectively. The hippocampus showed the majority of interregional associations, suggesting a
focus of inflammatory control between these regions.
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Background
Over sixty-five million people worldwide and three million
people in the USA have epilepsy [1], 15–20 % of whom
are medically refractory [2]. Of these, mesial temporal
lobe epilepsy (mTLE) defines the majority, accounting
for 60–75 % of epilepsy patients undergoing surgery
[3]. No consensus has been reached regarding the
mechanisms underlying epileptogenicity, although over
the past decade, increasing evidence has supported the
contribution of inflammatory processes in promoting
its occurrence [4–6].
Little is known regarding the postulated neuroinflam-
matory mechanisms in epilepsy; however, inflammation-
related mediators have been implicated in a number of
studies. Preclinical models of epilepsy have revealed
changes in a few brain inflammatory mediators [7–9];
however, only recently have clinical investigations fo-
cused on peripheral markers of inflammation [10–17].
Findings of elevated blood cytokine levels in epilepsy
patients have stimulated interest in brain tissue levels of
inflammation-related mediators [10, 12]. Importantly,
one study showed that neurosurgical resection of a small
epileptic focus significantly reduced elevated blood levels
of interleukin (IL)-1β, tumor necrosis factor (TNF)-α,
and macrophage inflammatory protein (MIP)-1α but not
IL-6 or TGF-β that were also elevated in mTLE [11].
Thus, it is likely that the source of these mediators was,
at least in part, within the central nervous system.
Cells of both peripheral (e.g., leukocytes) and brain
(e.g., microglia, astrocytes, neurons) origin produce a
plethora of inflammation-related mediators. Cytokines,
chemokines, and certain vascular-related mediators regu-
late the inflammatory state locally and communicate this
to other tissues. In the brain, such mediators activate
microglia and astrocytes, alter cerebrovascular function,
act as chemoattractants, affect the infiltration of periph-
eral inflammatory cells, and/or promote cellular prolifera-
tion, survival, or death. They can also affect ionic fluxes,
neurotransmission, and neural cell-cell communications
through a variety of mechanisms [18].
Local inflammatory responses may be an important
factor in chronic epilepsies, mediating secondary tissue
damage and increasing the likelihood of seizures and
their recurrence. For example, in epilepsy patients,
several studies have identified fluctuations in circulating
inflammatory cells [13, 19–21], as well as the infiltration
of peripheral blood cells within injured and epileptic
brain [21–26]. Regions of neuronal death and dysfunc-
tion in epileptogenic tissues have been associated with
increased leukocyte numbers and altered blood levels of
inflammatory mediators [11, 13, 27–29]. Moreover, the
chemokine CCL21, produced by neurons after insult or
injury, can be packaged into vesicles for transport along
axons; its release activates microglia via their CXCR3
receptors, which may account for remote microglial acti-
vation [30]. Areas of highly concentrated afferent input,
such as the entorhinal cortex with its reciprocal connec-
tion with the hippocampus, may be particularly vulnerable
under such conditions producing a site of epileptogenicity
remote from the site of the original injury [31].
Inflammatory mediators, produced by either blood or
brain cells, can uniquely instigate brain inflammation,
with little or no effect on the extracranial environment
[23]. Thus, the neuroinflammatory milieu at the site of
epileptogenesis is likely related to seizure onset, recur-
rence, and/or resistance to antiepileptic drug (AED)
treatments.
Characterization of inflammation-related mediator
levels at the epileptic focus will aid in further under-
standing these phenomena as well as better defining the
set of relevant targets for novel epilepsy therapies.
Moreover, although epilepsy-associated alterations in
inflammation-related mediators at the site of epilepto-
genesis may not be directly reflected in the systemic
circulation, these changes could indirectly affect circu-
lating inflammatory mediators and cells in such a way
that permits minimally invasive detection (i.e., in the
blood or cerebral spinal fluid (CSF)).
Unfortunately, there have been few investigations of
local alterations in inflammatory mediators within or
around the site of epileptogenesis, particularly in freshly
resected human brain tissue [18]. In the present study,
brain levels of 25 cytokines, chemokines, and vasoactive
proteins were quantified in soluble protein extracts of fresh
frozen, surgically resected temporal cortex, entorhinal cor-
tex, and hippocampus from 58 epileptic and 4 nonepileptic
patients. To our knowledge, direct, simultaneous quantifi-
cation of multiple inflammation-related mediators (e.g.,
pro- and anti-inflammatory, immune, and vascular effec-
tors) in resected human epileptic and nonepileptic brain
tissue has not previously been accomplished.
Methods
Participants
This study was undertaken through an institutional review
board approved process at the Henry Ford Health System
(Detroit, MI, USA) where the harvest of the tissues took
place between 2002 and 2008. Subsequent analyses took
place at the Spectrum Health System and Michigan State
University (Grand Rapids, MI, USA). Inflammation-
related mediator brain levels were determined in a series
of 62 neurosurgical cases (Tables 1 and 2; Additional file 1
(Patient_Data_Repository.xlsx, available online)), 58 of
which were focal epilepsy patients undergoing surgical re-
section for medically resistant epilepsy. Four nonepileptic
cases were included in the study, involving (1) intratu-
moral (glioblastoma) hemorrhage with herniation; (2)
putaminal hypertensive hemorrhage with middle cerebral
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artery infarction and herniation; (3) middle cerebral artery
aneurysm hemorrhage with herniation; and (4) acute sub-
dural hematoma with temporal contusion and herniation.
Clinical specimens
The hippocampus, entorhinal cortex, and temporal cortex
specimens were flash frozen in liquid nitrogen immedi-
ately upon resection and stored in polyethylene screw-cap
tubes below −70 °C. Each specimen was homogenized at
the same tissue concentration in order to improve com-
parisons. Brain pieces were dissected (100–200 mg,
avoiding blood and white matter as much as possible)
and pulverized on dry ice, transferred to pre-weighed
polyethylene tubes on dry ice, weighed, and immediately
sonicated in 5 vol. ice cold buffer H (100 mM potassium
phosphate (pH 7.4), 10 mM ethylenediaminetetraacetic
acid (EDTA), 1 mM dithiothreitol containing Cømplete®
Protease Inhibitor (Roche)), then centrifuged at 15K×g
for 20 min at 4 °C. A small portion of each supernatant
was assayed for total protein (microplate Bradford
assay), and the remainder of the soluble protein ex-
tracts split into several aliquots that were stored frozen
below −70 °C.
Measurements
For assays, tissue extracts were thawed on ice, differen-
tially diluted for the various VPLEX® assay sets (Additional
file 2: Table S1A) in Buffer H, and assayed in duplicates.
This study utilized ultrasensitive (fg/mL range) multiplex
enzyme immunoassays (custom-designed nine-plex human
array plates, Meso Scale Discovery (MSD), Gaithersburg,
MD). The multiplex assay plates were processed according
to the manufacturer’s instructions and read on the MSD
Sector 6000 electrochemiluminescence plate scanner
(MSD). Each VPLEX® set was accompanied by sets of
mixed calibrator standards provided by the manufacturer,
with seven serial dilutions in duplicates on each plate, to
serve as a standard curve for the analytes measured. Prior
studies (K. Strauss, unpublished data) established the ap-
propriate dilution of protein extracts to minimize signal
suppression and yield reproducible standard curves. Blanks
containing the diluent only (i.e., no tissue) were also in-
cluded in each study set. Analyte concentrations were ex-
trapolated only from within the ranges for each standard
curve, with coefficient of correlation, R2 ≥ 0.98. Lower
limits of detection (LLOD) and quantification (LLOQ)
were determined from these curves. LLOD was the mean
background from blanks plus 6 standard deviations above
the mean background value. LLOQ was designated as the
point on each standard curve above which the coefficient
of variation (i.e., standard deviation/mean) of calibrator
concentrations was less than 15 %. None of the brain ex-
tract values approached the upper limits of any assay.
Values below the LLOD were assigned a value of zero. For
values between the LLOQ and LLOD, a value of half the
LLOQ was assigned for analysis. Mass concentrations
in the original specimen were calculated by accounting
for assay volume, dilution at homogenization, differen-
tial dilution at assay (depending on the VPLEX® set),
and normalization to tissue wet weight (picogram ana-
lyte per gram tissue). These concentrations approxi-
mate tissue concentrations when the specific gravity of
the brain tissue is close to 1 g/mL [32].
Statistics
To determine which inflammation-related mediators
might be germane to recurrent seizure disorders, two
primary hypotheses were addressed in this study. These
were as follows: (1) inflammatory mediator levels would
be greater in brain regions proximal vs. distal to the
Table 1 Study enrollee demographics by Engel classification.
Enrollees were operated for mTLE by a single surgeon (KE) and
followed for more than 18 months postsurgically. Individual
case details can be found in the Additional file 1, available
online
Total enrolled Side resected Gender Mean age
(Y), 39 ± 1(N) 62 Right, 32 Left, 30 Female, 24 Male, 38
Engel
classification
Modified class (n) % Total
1A “1” 39 63 % 38 ± 1
1D “1D” 7 11 % 45 ± 3
2A “2” 1 2 % 37 ± 2
2B “2” 4 6 %
2D “2” 1 2 %
3A “3” 5 8 % 41 ± 2
Unclassified – 1 2 % –
Nonepileptic “Ø” 4 6 % 65 ± 3
Table 2 Established epilepsy risk factors and clinical variables.
Individual case details can be found in the Additional file 1,
available online




Closed head injury 15 40.13 7/8 3/12
Febrile 11 32.91 8/3 4/7
Infection 5 38.00 2/3 0/5
Developmental 4 42.50 0/4 1/3
Hypoxic Injury 4 37.00 1/3 1/3
Mild head injury 4 40.75 2/2 2/2
Lesional 3 32.33 2/1 0/3
Not Known 12 38.83 7/5 3/9
Nonepileptic 4 63.50 3/1 0/4
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epileptogenic focus in epilepsy cases and (2) mediators
important in a recurrent seizure disorder would show
different levels in epilepsy vs. nonepilepsy cases. Hy-
pothesis (1) was tested using multiple analyses of vari-
ance (MANOVA) with brain region repeated measures,
and hypothesis (2) tested using two-way ANOVA (brain
region × epilepsy status). The criterion for rejecting the
null hypothesis that there was no difference between
group means was p < 0.05, unless otherwise noted.
For each mediator, outliers (on the right) were re-
moved based upon the generalized extreme Studen-
tized deviate test (α < 0.005, one-sided) [33]. In cases
where there were significant main and specific effects,
but no significant post hoc result (p > 0.05; Tukey’s
honest significant difference test, the Tukey-Kramer
method (Tukey’s HSD)), non-parametric analyses (i.e.,
Wilcoxon rank sum test or Kruskal-Wallis for mul-
tiple comparisons) were initiated to mitigate the ef-
fects of large interindividual mediator level variability.
Statistical analyses were carried out using JMP 11 soft-
ware (SAS Institute Inc.). Note that full analyses of
the data using log10 transformation for normalization
yielded virtually identical results to those presented
below.
In the figures, individual case data are in red (epileptic)
or blue (nonepileptic), the grand mean is indicated by a
horizontal line, diamond center lines indicate group
means, and diamond upper and lower triangles indicate
the 95 % confidence interval.
Secondary analyses compared the mediator levels
in all three tissues with each secondary independent
variable using two-way ANOVA (brain region × sec-
ondary variable). These variables included the follow-
ing: age at surgery (years); side of the brain (L/R);
gender (M/F); epilepsy duration (years); Engel classi-
fication (modified to a five-point scale including
nonepileptic, 1A, 1D, 2A–C, 3A,B); epilepsy risk fac-
tor (nonepileptic, lesional, moderate-to-severe closed
head injury (CHI), mild CHI, developmental, febrile,
or infection); and pathology/imaging reports (hippo-
campus-only abnormalities, cortex-only abnormalities,
or both).
To determine whether mediator values were linearly
correlated, levels in each brain region were compared
using multivariate analysis. Due to the large number
of simultaneous comparisons (i.e., 25 mediators in
three brain regions gives 2775 pairwise comparisons),
a high degree of type I error was expected. To achieve
acceptable rates of type I and type II errors, a more
stringent type I error (α′ = 0.0001, df = 73, r ≥ 0.4340)
was used to select significant correlations; however, all
significant comparisons with correlation coefficient
99.9 % confidence intervals that overlapped zero were
eliminated.
Results
Soluble protein extracts from fresh frozen surgically
resected human hippocampus, entorhinal cortex, and
temporal cortex specimens from 58 medically refrac-
tory epilepsy and 4 nonepileptic neurosurgical cases
(Tables 1 and 2) were assayed for 25 inflammation-
related mediators using ultrasensitive multiplex en-
zyme immunoassay technology (see “Methods” section,
Additional file 2: Figures S2A - S2AA). The primary in-
dependent variables for the study were the brain region
and preoperative epilepsy status.
Variability in mediator measurements
Median mediator values varied over 4 orders of magni-
tude, and interindividual variability was great, even after
outlier removal (Additional file 2: Table S3B). Variability
was examined using coefficients of variation (CV) calcu-
lated for each mediator, between the brain regions and
by the epilepsy status (Additional file 2: Tables S3C–E).
The grand mean CV for all mediators was 125 %, with
tissue means of 114 % in the hippocampus, 130 % in the
entorhinal cortex, and 132 % in the temporal cortex.
The highest variability was seen with VEGF (236 %), IL-
2 (232 %), IL-6 (195 %), IL-8 (195 %), and IL-10 (183 %)
levels. Interestingly, IL-2 and IL-10 had high variability
across all tissues independent of epilepsy status, whereas
VEGF, IL-6, and IL-8 showed greater variability in epi-
leptic compared to nonepileptic tissues (Additional file
2: Tables S3D, E).
Brain mediator levels
Levels of 23 inflammation-related mediators were de-
tectable in the majority of specimens. The exceptions
were granulocyte-macrophage colony-stimulating factor
(GM-CSF) (74 % tested negative; see Additional file 2:
Tables S3F, G) and IFN-γ (94 % of specimens tested
negative).
Most of the brain tissue examined did not exhibit de-
tectable GM-CSF (see Table 3 note 4, Additional file 2:
Figure S2H); however, GM-CSF was present in the
hippocampus (15/48 epilepsy and 0/3 nonepileptic
cases), entorhinal cortex (3/58 epilepsy and 1/4 nonepi-
leptic cases), and temporal cortex (22/55 epilepsy and 3/
4 nonepileptic cases). Entorhinal cortical GM-CSF levels
were lower overall (Table 3; p < 0.005 Tukey’s HSD).
This was further supported by examining the number of
nonzero GM-CSF values in each brain region (Add-
itional file 2: Table S3G(A–C)). There was significant
nonhomogeneity between the brain regions (p < 0.0001
chi-square, df = 2), with entorhinal cortex showing the
lowest incidence of GM-CSF-positive cases. In addition,
nonhomogeneity was shown between the brain region and
epilepsy status groups (p < 0.001 chi-square, df = 5) (Add-
itional file 2: Figure S2H, Table S3G(C)).
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Similarly, most of the brain tissues examined did not ex-
hibit detectable IFN-γ levels (see Table 3, Additional file 2:
Figure S2U, Table S3H(A–C)) and no epilepsy-related
differences could be discerned. However, IFN-γ was more
often detected in the hippocampus (10/51 cases) than in
the entorhinal cortex (0/62) or temporal cortex (1/59)
(p = 0.0001 chi-square, df = 2). As with GM-CSF, there was
nonhomogeneity between groups with respect to the brain
region and epilepsy status (p = 0.004 chi-square, df = 5).
Chemokines
Eotaxin levels (Table 3) showed brain region-specific
differences over all cases using brain region repeated
measures (MANOVA; p < 0.0001). Hippocampal eotaxin
levels were higher than those in the entorhinal and temporal
cortices (Fig. 1a, p < 0.001 post hoc Tukey’s HSD). Epilepsy-
related differences in eotaxin were also apparent. Eotaxin
levels were higher in nonepileptic cases (Table 4, Fig. 1b)
and, specifically in the entorhinal cortex using epilepsy ×
Table 3 Inflammation-related mediators by brain region
Mediatora
(pg/g tissue)




epilepsy (±) × region
P valuec
Mean SEM N Mean SEM N Mean SEM N
Eotaxin 627**** 67 51 404 40 62 307 42 59 <0.0001 <0.0001
IP-10 3597** 453 51 6213 1292 59 7004 1413 59 0.0306 0.0038
MCP-1 8051 1199 51 4551* 465 60 8440 1803 58 0.0045 0.1923
MCP-4 839 89 51 545* 35 62 676 152 57 0.0011 0.3751
MIP-1α 1008 189 51 590 124 62 2187**** 361 59 0.0001 <0.0001
MIP-1β 2362 311 51 1636 208 61 3306*** 437 59 0.0037 0.0153
TARC 666 111 51 501 49 61 855 205 59 0.1047 0.3991
GM-CSFd 3062 710 51 470**** 230 62 2579 400 59 <0.0001 0.0009
IFN-γd 33.1**** 10.9 51 0 0 62 1.56 1.56 59 0.0143 0.0008
IL-1α 992** 162 51 3616** 372 62 2576** 271 58 <0.0001 <0.0001
IL-1β 13.8** 2.2 51 27.8** 3.9 62 39.7** 5.0 57 <0.0001 0.0002
IL-2d 38.3**** 7.9 49 4.16 1.83 62 7.97 2.27 59 <0.0001 <0.0001
IL-4 11.7**** 1.2 49 7.17 0.40 62 6.45 0.44 59 0.0010 <0.0001
IL-6 33.4 8.2 51 34.8 8.5 60 60.8 15.2 57 0.1409 0.0161
IL-8 570 121 51 933 251 61 1473* 331 57 0.0029 0.0259
IL-10d 4.21 0.75 51 1.49** 0.47 61 3.37 0.85 59 0.0225 0.1399
IL-12/23 p40 72.9 14.8 51 97.9 12.8 61 88.2 13.3 58 0.1490 0.1273
IL-12 p70 5.17 0.68 50 2.65*** 0.43 62 3.59 0.29 58 0.0494 0.0019
IL-17A 949**** 112 49 378 44 62 252 28 59 <0.0001 <0.0001
TNF-α 5.89 0.75 51 3.16 0.67 60 5.26 0.85 57 0.1176 0.0518
TNF-β 3.85 0.89 49 8.52**** 0.58 62 4.90 0.56 59 0.0143 <0.0001
VEGF 7716*** 1865 49 3553 1199 62 1889 720 59 0.0231 0.0465
CRP 26,540 2222 49 22,069 1435 62 15,624**** 1115 59 <0.0001 <0.0001
ICAM-1 12,088** 1110 50 9243 786 62 8291 897 58 0.0035 <0.0001
VCAM-1 21,887 4754 51 21,351 3659 62 14,427 2632 59 0.0103 <0.0001
Abbreviations: Eotaxin (also known as (aka) CCL-11), IP-10 interferon gamma-induced protein 10 (aka CXCL-10), MCP-1 monocyte chemoattractant protein 1 (aka
CCL-2), MCP-4 monocyte chemoattractant protein 4 (aka CCL-13), MIP-1α macrophage inflammatory protein 1-alpha (aka CCL-3), MIP-1β macrophage inflammatory
protein 1-beta (aka CCL-4), TARC thymus- and activation-regulated chemokine (aka CCL-17), GM-CSF granulocyte-macrophage colony-stimulating factor (aka CSF2),
IFN-γ interferon gamma, IL interleukin, IL-8 (aka CXCL-8), TNF tumor necrosis factor, VEGF vascular endothelial growth factor, CRP C-reactive protein, ICAM-1 intercellular
adhesion molecule 1 (aka CD54) , VCAM-1 vascular cell adhesion molecule 1 (aka CD106)
*p ≤ 0.01, Wilcoxon/Kruskal-Wallis; **p < 0.05, Tukey's HSD; ***p < 0.01, Tukey’s HSD; ****p < 0.001, Tukey’s HSD
aMediator values in pg/g tissue, N is number of observations, SEM = (standard deviation/N1/2). The total number of specimens assayed was as follows:
hippocampus = 51, entorhinal cortex = 62, temporal cortex = 59; differences from these values indicate outlier removals. Case data, distributions, and summary
statistics can be found in Additional file 2: Figures S2A - S2AA, and the complete data set in Additional file 1
bRepeated measures MANOVA of mediator levels by brain region, brain region effect. Italicized P values indicate significant post hoc comparisons
cTwo-way ANOVA epilepsy status (±) × brain region, main effect. See Table 4 for post hoc comparisons
dGM-CSF and IFN-γ exhibited 74 and 94 % assay values of zero (below the lower limit of detection), and assays for IL-2 and IL-10 had 65 and 59 % zero values,
with more than half the zero values in the cortical region specimens
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brain region repeated measures (MANOVA; epilepsy
effect, p < 0.01 Tukey’s HSD).
Levels of IP-10 showed no regional differences (Fig. 1c),
likely due to the high variance in cortical specimens.
Although IP-10 levels were greater in nonepileptic cases
overall, and specifically in the entorhinal cortex, when
considering the epilepsy effect and epilepsy × brain region
interaction (both p < 0.001 Tukey’s HSD), these effects
may have been due to a few extreme nonoutlier values in
the cortical specimens (see Additional file 2: Figure S2B).
Monocyte chemoattractant protein (MCP)-1 and MCP-
4 levels had brain region-specific but no epilepsy-related
differences (Table 3). Nonparametric analyses suggested
that entorhinal cortex levels were lower for each than in
the hippocampus or temporal cortex (post hoc Wilcoxon/
Kruskal-Wallis, p = 0.002 and p = 0.0005, respectively).
Inspection of the individual case data showed that this
was true in 67 % of cases for MCP-1 (Additional file 2:
Figure S2C) and in 53 % of cases for MCP-4 levels
(Fig. 1d, Additional file 2: Figure S2D).
MIP-1α levels showed brain region-specific differences
overall (Fig. 1e, Table 3). Temporal cortical MIP-1α
levels were greater than in the entorhinal cortex or
hippocampus (p < 0.01 Tukey’s HSD). MIP-1β levels
showed similar region-specific differences overall (Fig. 1f,
brain region effect p = 0.0037). The temporal cortical
MIP-1β levels were higher than in the entorhinal cortex
(Table 3, p = 0.002 Tukey’s HSD) but not different from
the hippocampal levels. No epilepsy-related MIP-1α or
MIP-1β differences were detected.
Fig. 1 a Eotaxin levels in human brain specimens. Overall, the hippocampal levels were greater than the entorhinal and temporal cortex.
b Epilepsy-related eotaxin differences. Brain levels of eotaxin were greater among nonepileptic cases overall, and the nonepileptic entorhinal
cortex eotaxin was greater than in the epileptic entorhinal cortex. c IP-10 levels were not significantly different between brain regions. d MCP-4
levels appeared lower in the entorhinal cortex than the other tissues. e MIP-1α and f MIP-1β levels in the human brain showed similar regional
differences. In all graphs, blue = nonepileptic cases, red = epileptic cases. Data points are means of duplicate measurements; diamond graphs show
the grand mean for all cases as a horizontal line, diamond center line indicates group mean, upper and lower triangles indicate the 95 % confidence
intervals. Histograms show group mean ± standard error; solid lines show within epilepsy status, and dashed lines show between epilepsy status
group differences. Post hoc testing: **p < 0.001; *p < 0.01; §p < 0.05, Tukey’s HSD; ¶p < 0.01, non-parametric Wilcoxon/Kruskal-Wallis, unless
otherwise noted
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Brain levels of the thymus- and activation-regulated
chemokine (TARC) showed neither brain region- nor
epilepsy-related changes. The temporal cortex from epilep-
tic cases had very high TARC levels; however, this was ob-
scured by a high variability of TARC levels in the epileptic
temporal cortex (Additional file 2: Figure S2G, Table S3E).
Cytokines
Interleukin (IL-)1α levels showed graded brain region-
specific differences overall (Fig. 2a, Table 3) with greatest
expression in the entorhinal cortex followed by that in the
temporal cortex and, lastly, the hippocampus (p < 0.03
post hoc Tukey’s HSD). No epilepsy-related differences
were discerned. On the other hand, IL-1β levels (Fig. 2b,
Table 3) showed both graded brain region-specific dif-
ferences and epilepsy-related effects. IL-1β levels were
greatest in the temporal cortex, intermediary in the en-
torhinal cortex, and lowest in the hippocampus (Table 3;
p < 0.05 Tukey’s HSD). In addition, nonepileptic brain
regions showed greater IL-1β levels than epileptic brain
regions overall (Table 4; epilepsy × brain region ANOVA,
epilepsy effect p < 0.04, p < 0.05 Tukey’s HSD).
IL-2 (Fig. 2c) and IL-4 (Fig. 2d) brain levels showed
similar patterns of regional differences. IL-2 was elevated
in the hippocampus compared to either the entorhinal
or temporal cortices (Table 3, p < 0.005 Tukey’s HSD).
A significant epilepsy status × brain region repeated
measures interaction (p < 0.03) was noted, with IL-2
levels in the nonepileptic temporal cortex exceeding
those in the epileptic temporal cortex (p < 0.01 Tukey’s
HSD). Similarly, hippocampal IL-4 levels were elevated
compared to other tissues (Table 3, p < 0.001 Tukey’s
HSD), but no epilepsy-related differences were observed.
IL-6 levels were numerically highest in the temporal
cortex but variability in both epileptic and nonepileptic
cases confounded the analysis (Additional file 2: Figure
S2M, Tables S3C–E, H). Although there were no overall
differences in IL-6 between brain regions (Fig. 2e), there




Hippocampus Entorhinal cortex Temporal cortex
Nonepileptic Epileptic Nonepileptic Epileptic Nonepileptic Epileptic
Eotaxin 772 ± 180a,** 618 ± 71 986 ± 355a,** 364 ± 31 558 ± 401a,** 289 ± 36
n 3 48 4 58 4 55
IP-10c 4.96 ± 1.79 3.51 ± 0.47 24.0 ± 17.4b,** 5.26 ± 0.97 7.68 ± 5.27 6.96 ± 1.48
n 3 48 3 56 4 55
MIP-1αd 698 ± 494 1027 ± 199 2192 ± 1463 480 ± 80 873 ± 437 2283 ± 383
n 3 48 4 58 4 55
IL-1βd 29.1 ± 15.3a,** 12.9 ± 2.1 59.0 ± 26.4a,** 25.7 ± 3.7 49.3 ± 39.2a,** 39.0 ± 4.8
n 3 48 4 58 4 53
IL-2 24.6 ± 24.6 39.2 ± 8.3 11.3 ± 6.7 3.67 ± 1.90 30.1 ± 30.1b,*** 6.37 ± 1.25
n 3 46 4 58 4 55
IL-6d 149 ± 38a,**** 26.1 ± 7.2 65.2 ± 47.6 33.2 ± 8.6 61.7 ± 35.2 60.7 ± 16.0
n 3 48 3 57 3 54
IL-12 p70 2.26 ± 2.26 5.35 ± 0.71a,** 1.94 ± 1.94 2.69 ± 0.44a,** 0 3.79 ± 0.28a,**
n 3 47 4 58 3 55
TNF-αd 5.04 ± 3.21 5.95 ± 0.77 7.60 ± 4.44 2.93 ± 0.67 0.79 ± 0.79 5.51 ± 0.88
n 3 48 3 57 3 54
CRPc 50.5 ± 37.4a,**** 25.5 ± 18.8 39.7 ± 11.7a,**** 20.9 ± 12.1 23.8 ± 7.9a,**** 15.0 ± 1.0
n 2 47 4 58 4 55
ICAM-1c 16.0 ± 8.7 11.9 ± 1.1 19.1 ± 8.1b,**** 8.57 ± 0.59 6.60 ± 2.26 8.42 ± 0.95
n 2 48 4 58 4 54
VCAM-1c 131 ± 9b,**** 15.0 ± 2.9 75.7 ± 22.5b,**** 17.6 ± 3.1 49.9 ± 16.1b,**** 11.9 ± 2.3
n 3 48 4 58 4 55
**p < 0.05; ***p < 0.01; ****p < 0.001, post hoc Tukey’s HSD
aEpilepsy effect; overall epileptic vs. nonepileptic cases. Only the greater set of values are marked
bEpilepsy × brain region interactions, epileptic vs. nonepileptic cases in individual brain region(s). Only the greater set of values are marked
cThe units of these mediators are in ng/g tissue
dThese mediators were elevated in the blood of mTLE patients [11]; neurosurgical resection reduced the blood levels of TNF-α, IL-1β, and MIP-1α, but not IL-6
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was a significant epilepsy × repeated measures brain re-
gion interaction (p < 0.02). The hippocampal IL-6 levels
were greater in nonepileptic compared to epileptic cases
(Table 4, p < 0.001 Tukey’s HSD).
Overall, IL-8 levels in the temporal cortex were greater
than in the hippocampus or entorhinal cortex (Table 3,
Fig. 2f, p < 0.008 post hoc Wilcoxon/Kruskal-Wallis),
with the entorhinal cortical levels intermediary to these
regions (not significantly different (n.s.d.)). In contrast,
IL-10 levels were higher in the hippocampus than in the
entorhinal cortex (Fig. 2g, p < 0.05 Tukey’s HSD), with
intermediary levels (n.s.d.) found in the temporal cortex.
IL-17A levels showed brain region-specific differences,
with the hippocampal levels higher than both the entorhi-
nal and temporal cortices (Table 3, p < 0.001 Tukey’s HSD).
Neither epilepsy-related differences nor brain region × epi-
lepsy interactions were detected for brain IL-17A levels.
Bioactive IL-12 is a p35:p40 heterodimer-designated IL-
12 p70. The p40 subunit also binds with other proteins,
such as p17, to form IL-23. Two IL-12-related assays were
performed, the IL-12/23 p40 assay that detected p40 in all
its forms except for IL-12 p70, and the IL-12 p70 assay
which detected only intact heterodimers (Paul Grulich,
MSD Scientific Support Group, personal communication).
Fig. 2 Brain region differences in interleukin (IL) levels. a IL-1α and b IL-1β levels differed between all three brain regions. c IL-2 and (d) IL-4 levels
were elevated in the hippocampus. (e) IL-6 levels showed high variability without brain region-specific or epilepsy-related differences. f IL-8 levels
were higher in the temporal cortex than the other brain regions, whereas g IL-10 levels were higher in the hippocampus than in the entorhinal
cortex, and h IL-17A levels were higher in the hippocampus than the entorhinal cortex and temporal cortex. For graphics details, see Fig. 1
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Though IL-12/23 p40 levels showed neither brain re-
gion- nor epilepsy-related differences (Fig. 3a), the het-
erodimer IL-12 p70 exhibited both brain region-specific
and epilepsy-related differences. IL-12 p70 was increased
in the hippocampus compared to the entorhinal cortex
(Fig. 3b, p < 0.005 Tukey’s HSD). A bimodal distribution
might be present for IL-12 p70 but could not be con-
firmed because most measurable values were close to the
lower limit of quantification. Epileptic brain had higher
levels of IL-12 p70 than nonepileptic cases (Table 4, epi-
lepsy effect p < 0.03, p < 0.05 Tukey’s HSD).
Brain levels of IL-12/23 p40 were much greater than
that of IL-12 p70 (Fig. 3a–d, Additional file 2: Table
S3B). Mean p40 to p70 molar ratios (Fig. 3c, Additional
file 2: Figure S2AA) were 13 ± 4 in the hippocampus,
23 ± 5 in the entorhinal cortex, and 31 ± 6 in the temporal
cortex, suggesting that only a small proportion of the
total p40 tissue content was in IL-12 p70. In addition,
the mean p40:p70 molar ratio was higher in the tem-
poral cortex than in the hippocampus (Fig. 3c, repeated
measures MANOVA p = 0.0271, p < 0.02 Tukey’s HSD).
Moreover, the IL-12 p70:p40 molar ratio showed lower
values in the entorhinal cortex compared with other
tissues (Fig. 3d, Additional file 2: Figure S2Z, repeated
measures MANOVA, brain region effect p = 0.0007,
p ≤ 0.01 Tukey’s HSD). Both of the latter findings were
consistent with elevated hippocampal IL-12 p70 levels
(Fig. 3b).
TNF-α showed no brain region-specific or epilepsy-re-
lated differences (Table 3). Nonetheless, case data showed
that the entorhinal cortical levels were lower than those in
the hippocampus and temporal cortex in most individuals
(69 and 52 %, respectively, Additional file 2: Figure S2S). In
contrast, TNF-β brain levels were highest in the entorhinal
cortex overall (Fig. 4b, p < 0.001 Tukey’s HSD). Data
showed the entorhinal cortical levels to be higher than in
the hippocampus and temporal cortex in 76 and 83 % of
cases, respectively (Additional file 2: Figure S2T).
Vascular mediators
Hippocampal VEGF levels were two- and fourfold
greater than in the entorhinal and temporal cortical
regions, respectively (Table 3, Fig. 4c, p < 0.01 Tukey’s
HSD). Nonparametric analyses suggested graded VEGF
levels, with the hippocampus showing the highest levels
followed by the entorhinal cortex, and lastly, the temporal
cortex (p < 0.0002 Wilcoxon/Kruskal-Wallis). No epilepsy-
related differences were observed; however, there was
increased VEGF variation in epileptic tissue specimens
(Additional file 2: Figure S2V, top right) that may have
obscured differences between epileptic and nonepileptic
VEGF levels (Additional file 2: Tables S3C, E, I).
Brain levels of C-related protein (CRP) were lower in the
temporal cortex than in the hippocampus or entorhinal
cortex (Fig. 5a, p < 0.01 Tukey’s HSD). Moreover, two-way
ANOVA showed 50, 53, and 63 % lower CRP levels in the
Fig. 3 IL-12 brain levels. a IL-12/23 p40 levels did not show brain region-specific differences. b The heterodimeric IL-12 p70 showed brain region-
specific differences, with higher levels in the hippocampus than in the entorhinal cortex. c The molar ratio of IL-12/23 p40 to IL-12 p70 (p40:p70)
was elevated in the temporal cortex compared with the hippocampus and entorhinal cortex (§p < 0.02, Tukey’s HSD). d IL-12 p70:p40 molar ratios
were depressed in the entorhinal cortex (compared to the hippocampus and temporal cortex, **p≤ 0.01 Tukey’s HSD), despite higher p70 levels
in the hippocampal specimens. For graphics details, see Fig. 1
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epileptic hippocampus, entorhinal cortex, and temporal
cortex, respectively (Fig. 5b, Table 4, epilepsy effect p <
0.0001, all p values <0.05 Tukey’s HSD).
Intercellular adhesion molecule (ICAM)-1 levels were
highest in the hippocampus compared to the cortical
regions overall (Table 3, Fig. 6a, p < 0.03 Tukey’s HSD).
While there was no significant epilepsy-related effect,
there were significant epilepsy × brain region repeated
measures interactions (p = 0.0008). ICAM-1 levels in the
nonepileptic entorhinal cortex were higher than in the
epileptic cases (Fig. 6b, p < 0.001 Tukey’s HSD).
Vascular cell adhesion molecule (VCAM)-1 levels did
not appear different across brain regions overall (Fig. 6c)
but showed multiple effects among the nonepileptic
cases (Table 4, epilepsy effect p < 0.0001, brain region
effect p < 0.0001, epilepsy × brain region interaction p <
0.0001). Specifically, VCAM-1 levels were greater in each
of the nonepileptic brain region cases compared to the
epileptic cases (Fig. 6d, p < 0.001 Tukey’s HSD). Also,
VCAM-1 levels in the nonepileptic hippocampus were
greater than in either the nonepileptic entorhinal cortex or
temporal cortex (Fig. 6d, Table 4, p < 0.05 Tukey’s HSD).
Fig. 4 a TNF-α levels in the human brain did not show region-specific differences by post hoc testing. However, on a case-by-case analysis (a),
the entorhinal cortex TNF-α levels were lower than in the hippocampus or temporal cortex for 59 % of all individuals. b TNF-β brain levels were
higher in the entorhinal cortex, and higher than in the hippocampus or temporal cortex for 80 % of all individual cases. c VEGF levels were
greater in the hippocampus than in the entorhinal or temporal cortex. For graphics details, see Fig. 1
Fig. 5 a CRP (C-reactive protein) levels were the lowest in the temporal cortex compared to the hippocampus and entorhinal cortex. b CRP levels
were higher in the nonepileptic hippocampus and entorhinal cortex. For graphics details, see Fig. 1
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Secondary analyses
Secondary independent variables were also considered in
the analyses of these brain mediator levels. Differences
based upon gender, side of the brain resected, epilepsy
duration, age at surgery, presumptive epilepsy risk fac-
tors, surgical electrode placement prior to resection
(“phase 2”), and Engel outcome classifications were eval-
uated. Moreover, pathology and imaging findings were
also investigated as potential covariates.
Gender, side of brain, and epilepsy duration
None of the mediator levels differed with respect to
patient gender, side of the brain affected, or time since
seizure onset.
Age at surgery (years)
Age at surgery was a significant predictor only for the
hippocampal VCAM-1 (linear regression, R2 = 0.340,
p < 0.02) and IL-8 (R2 = 0.294, p < 0.05), both increasing
with age (Additional file 2: Figure S4A).
These findings brought into question the observed brain
region- and epilepsy-related differences. For VCAM-1, a
difference of 26 years in the mean age between epileptic
and nonepileptic groups yielded a difference of 39,650
pg/g tissue in the hippocampal VCAM-1 levels, accord-
ing to the predicted VCAM-1 vs. age fit line (Additional
file 2: Figure S4A). Nevertheless, the difference in the
hippocampal VCAM-1 levels between nonepileptic and
epileptic cases was over 200 % of this value (Table 4,
Fig. 6d). Brain region × epilepsy × age interactions were
significant (three-way ANOVA main effect p <0.0001,
triple interaction p = 0.013). Thus, age- and epilepsy-
related differences were confirmed for the hippocampal
VCAM-1 levels. Interestingly, although no other brain
region showed a significant correlation between VCAM-1
and age, the entorhinal cortex exhibited ~150 % and
the temporal cortex ~95 % of the predicted differences
between nonepileptic and epileptic cases according to
the hippocampal VCAM-1 vs. age fit line.
The findings for IL-8 differences were also supportive of
epilepsy-related differences in the hippocampus. Whereas
the nonepileptic hippocampal IL-8 levels were 300 % for
those expected by age alone (according to the predicted IL-8
vs. age fit line, Additional file 2: Figure S4A), the entorhinal
and temporal cortical levels were closer to predicted age-
related levels (88 and −53 %, respectively). Finally, analyses
Fig. 6 a, b ICAM-1 and (c, d) VCAM-1 levels in the human brain. a ICAM-1 levels were higher in the hippocampus than in the entorhinal or
temporal cortex (brain region repeated measures MANOVA p < 0.0007, p <0.03 Tukey’s HSD). b In nonepileptic cases, the entorhinal cortex
ICAM-1 levels were higher than in the epileptic cases (epilepsy × brain region MANOVA p < 0.0007, p < 0.001 Tukey’s HSD). c VCAM-1 levels
showed no brain region-specific differences over all cases. d VCAM-1 levels were higher in nonepileptic cases in all three regions (dashed
lines, epilepsy × brain region interaction p < 0.0001). In the nonepileptic hippocampus, VCAM-1 levels were elevated compared with other
brain regions (solid lines, p < 0.05 Tukey’s HSD). For graphics details, see Fig. 1. **p < 0.001, §p < 0.05, post hoc Tukey’s HSD
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of epilepsy status × age for each brain region showed
significant effects for IL-8 levels only in the hippocampus
(main effect p < 0.0001, epilepsy effect p= 0.0002, age effect
p= 0.554, interaction p= 0.642).
Epilepsy risk factors
Previously identified epilepsy risk factor(s), presumed to
have contributed to patients' recurrent seizures (Table 2),
were analyzed to find associations with inflammation-
related mediators in the brain. Other than the expected
brain region differences (brain region × epilepsy risk fac-
tor ANOVAs), several risk factor associations appeared
significant.
Multivariate screening analyses revealed that high VEGF
levels in the hippocampus were associated with mild
closed head injury (mCHI); elevated IP-10 and IL-12/23
p40 levels in the entorhinal cortex were associated with
the infection risk factor (Additional file 2: Figure S4B). No
temporal cortical mediator differences showed significant
associations with any presumptive epilepsy risk factor(s).
Univariate analyses suggested several other associations.
Overall IL-1α levels were higher in the infection subgroup
compared to CHI or febrile risk factor subgroups; overall
IL-6 levels were higher in the CHI subgroup compared
to the febrile subgroup; and overall MIP-1β levels
were higher in the mCHI subgroup compared to the
developmental, infection, febrile, or lesional risk factor
subgroups (Additional file 2: Figure S4B).
Phase 2 electrode placement
Several associations emerged between the mediators
assayed and prior placement of intracranial surface elec-
trodes for localization of epileptogenic foci. Cases that had
electrode placement prior to resection (n = 31) exhibited
higher levels of eotaxin, IL-1α, MCP-1, MCP-4, CRP, and
ICAM-1 over all brain regions combined and, specifically,
in both cortical regions (Additional file 2: Table S4I).
There were no mediator level differences noted in the
hippocampus, which might suggest that electrode place-
ment had minimal effect on nonadjacent brain structures.
Engel classification
Using a modified Engel classification score (Table 1),
several mediators appeared to be associated with Engel
outcome subgroups. The majority of associations observed
were between the nonepileptic group and the epileptic
subgroups; these differences were not described here
because they were reported above. Such differences
may reflect less on outcome after surgery and more on
neurophysiologic differences between nonepileptic and
epileptic cases. There were, nonetheless, several instances
of differences between Engel subgroups (Fig. 7, brain
Fig. 7 Differences in selected mediator levels correlated with a modified Engel outcome scale. Engel classifications were simplified to 1A, 1D,
“2,” and “3” (see Table 1, classifications 1A, 1D, 2A - 2D and 3A, respectively). The nonepileptic group is represented by “Ø”. HC hippocampus,
ERCx entorhinal cortex, TCx temporal cortex. Dashed lines show epileptic subgroup differences, **p < 0.001, *p ≤ 0.01, §p < 0.05 Tukey’s HSD vs.
subgroups indicated
Strauss and Elisevich Journal of Neuroinflammation  (2016) 13:270 Page 12 of 18
region ×modified Engel main effects p ≤ 0.002). Hippo-
campal MIP-1α and ICAM-1 levels were greater in the
Engel - 1D subgroup than those in the Engel-1A subgroup
(Fig. 7, top row; Engel effect p = 0.0060 and p = 0.0412,
respectively, p ≤ 0.02 Tukey’s HSD). The same is held for
ICAM-1 in the entorhinal cortex (brain region ×modi-
fied Engel interaction p = 0.0213, p < 0.05 Tukey’s HSD).
In the temporal cortex, MCP-4 levels were increased in
the Engel-2 subgroup compared with those in better
outcome Engel-1A and -1D subgroups (Fig. 7, bottom
row, left; brain region ×modified Engel interaction p =
0.0091, p < 0.01 and p < 0.04 Tukey’s HSD, respectively).
In addition, the molar ratio of IL-12 p70 (bioactive IL-
12) to its p40 subunit was increased in the worst out-
come (Engel-3) subgroup, compared to those in both the
Engel-1A and -1D subgroups (Fig. 7, bottom row, right;
brain region ×modified Engel interaction p = 0.0280, p <
0.05 Tukey’s HSD).
Pathology and imaging reports
Of the 55 cases with pathology and imaging report data,
84 % had observed hippocampal pathology, with two
thirds of these showing hippocampal sclerosis. Of the 55
cases, 44 % showed cortical pathology. Interestingly,
56 % had hippocampal with no cortical findings, but
only 15 % had cortical with no hippocampal findings.
An analysis was performed to interrogate differences
of inflammatory-related mediator levels with respect to
neuropathological findings (hippocampus only, cortex
only, or both). The phase 2 status was considered salient
to this analysis because half the cases underwent prior
surface electrode placement. Phase 2 status was taken
into account using two-way ANOVAs. Both pathology
and MRI reports were tested separately with the follow-
ing results. Cases in which both the hippocampal and
cortical abnormalities were reported by the pathologist
showed significantly (p < 0.05 Tukey’s HSD) increased
levels of MIP-1α (hippocampus), IL-17A (temporal
cortex), and ICAM-1 (temporal cortex). MIP-1α and
ICAM-1 results were complicated by significant inter-
action between neuropathologic findings and phase 2
status (phase 2+ cases had higher levels). The IL-17A
finding appeared more robust, as MR imaging showing
abnormalities in both regions was also associated with
increased IL-17A levels in the temporal cortex. In
addition, MR imaging abnormalities in both regions
were associated with elevated levels of TARC (entorhinal
cortex) and IP-10 (temporal cortex).
Cases in which only the hippocampal abnormalities
were reported by the pathologist were associated with
increased IL-1α levels (entorhinal cortex), and a trend
(p ≈ 0.05) was noted in the MR imaging-evident
hippocampus-only analysis as well. Thus, abnormal
findings in both the cortex and hippocampus may be
associated with increased proinflammatory mediator
levels such as IL-17A and IP-10 in the temporal cortex
or IL-1α and TARC in the entorhinal cortex.
Involvement of the hippocampus only may be associ-
ated with increased IL-1α levels in the entorhinal cor-
tex. Intriguingly, no mediator differences were observed
in cases with pathology or MR abnormalities in the cor-
tex only.
Mediator-to-mediator correlations
Another approach to understanding brain inflammatory
regulation is to identify groups of mediators with associ-
ated expression profiles. Robust mediator-to-mediator
associations were observed in 141 pairwise comparisons
across the hippocampus, entorhinal cortex, and temporal
cortex (p < 0.0001, see “Methods” section). These corre-
lations (Additional file 2: Figure S4C) were distributed
rather evenly, with each brain region having approxi-
mately one third of the associations. Of the 141, 70 %
were between different mediators within a single brain
region, 24 % were between different mediators in different
brain regions, and 6 % were individual mediators between
different brain regions. Only two negative correlations
were observed between region-specific mediators. The
hippocampal CRP and IL-12 p70 levels were inversely
associated, and the entorhinal cortex TNF-α levels were
inversely associated with hippocampal TNF-β levels.
Of the correlations of different mediators within a single
brain region, half were in the temporal cortex and one
quarter each were in the hippocampus and entorhinal
cortex. For correlations of different mediators in different
regions, 57 % were between the hippocampus and tem-
poral cortex, 36 % were between the hippocampus and
entorhinal cortex, and 7 % were between the entorhinal
and temporal cortices. These proportions may suggest
differential control of inflammation-related mediator
levels within/between these regions.
Individual mediator levels that correlated between differ-
ent brain regions were as follows: VCAM-1 levels corre-
lated between all three brain regions; MCP-1, IL-1α, IL-2,
and VEGF levels correlated between the entorhinal and
temporal cortices; ICAM-1 levels between the hippocam-
pus and entorhinal cortex; as well as IP-10 levels between
the hippocampus and temporal cortex. These interregional
associations indicate predominantly extrinsic (i.e., cerebral
or systemic) control of these brain mediator levels.
Interestingly, of the 141 mediator-to-mediator correla-
tions observed in these three brain regions, the majority
(78 %) were accounted for by eight mediators, namely,
eotaxin (22), ICAM-1 (17), MCP-1 (16), IL-4 (14), IL-6
(14), IL-8 (11), MIP-1α (9), and VCAM-1 (8). This
observation implies a hierarchical dynamic in which
mediators with multiple correlations may regulate,
directly or indirectly, the levels of other mediators.
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Conversely, there were several mediators that had three
or fewer correlations with mediators in any other tissue
(Additional file 2: Figure S4C, bottom). These included
GM-CSF and IFN-γ, for which most tissue values were
below the level of detection, IL-1α and VEGF which
were self-correlated between the temporal and entorhi-
nal cortices, as well as TNF-β. Moreover, in specific
brain regions, a few mediators had zero or one correl-
ation with other mediators.
Blood mediator levels vs. brain tissue content
Although usually considered intravascular mediators,
cytokines and chemokines in CSF and, by inference, in
the central nervous system (CNS) may be more concen-
trated than those found in the systemic circulation. For
example, during the first 10 days after severe head
trauma, patient CSF levels of IL-6 and TNF-α (but not
CRP) were greater than in the blood [34]. Also, at least
in lupus patients, MCP-1 and GM-CSF were present at
much higher levels in neural tissue than in the serum
[35]. In epilepsy patients, there were clear transients of
leukocyte and mediator changes immediately postictally
[19] leaving open the question as to whether there
were transient changes in the brain or at the site(s) of
epileptogenesis.
In order to rule out brain mediator content in the
present study being entirely due to blood levels, brain
levels were compared with published blood levels
(Additional file 2: Table S4J–K) and potential differ-
ences were identified. Not only were median MCP-1
levels in the brain greater than in peripheral blood, but
IP-10, MIP-1β, IL-1α, IL-8, IL-17A, VEGF, CRP, and
ICAM-1 levels appeared to exceed maximal blood
levels by two- to sixfold or more. In contrast, Yoshio et
al. [35] found no differences between serum and CSF
levels for IP-10 and IL-8 and greater levels in serum
than CSF for MIP-1β, IL-17A, and VEGF (IL-1α, CRP,
and ICAM-1 were not assayed). These comparisons
would seem to reveal the existence of neural-based
degradation mechanisms for these mediators.
Discussion
Mediator levels
Human epilepsy disorders exhibit peripheral cytokine
changes that may originate at sites of neural dysfunction
and contribute to seizure propagation (reviewed in [12]).
Sinha et al. [15] analyzed serum IL-1β, IL-2, IL-4, IL-6,
IFN-γ, or TNF-α detectability in 100 postictal patients
and 100 healthy controls. None of the age- and sex-
matched control subjects had detectable levels of any of
these cytokines, whereas among epilepsy patients, the
overall incidence was 74 %. Of the nine epilepsy patients
who had a lumbar puncture, CSF levels of these cyto-
kines were detectable in subject(s) with no serum levels.
Significantly, none of the subjects who were serum-
positive for a cytokine were CSF-negative for that cyto-
kine. Serum IL-6, IL-1β, TNF-α, and MIP-1α levels were
elevated in AED-resistant epilepsy patients and, in patients
undergoing resection of the epileptogenic region, IL-1β,
TNF-α, and MIP-1α levels decreased after 8 weeks post-
operatively [11]. These results implied that the epilepto-
genic brain tissue removed was either a direct or indirect
source of these mediators. Until now, there has been a
paucity of data on human brain tissue inflammation-
related mediator levels [10].
In the current study, however, none of these mediators
appeared to be elevated proximal to the site of epilepto-
genesis. In fact, IL-6, IL-1β, and MIP-1α levels were
higher in the temporal cortex than in the hippocampus,
and TNF-α showed no regional or epilepsy-related
differences, though levels in entorhinal cortex may have
been lower than either the hippocampus or temporal
cortex (see Additional file 2: Figure S2S). If both studies
are valid, and the patient samples represent the greater
population, then it must be concluded that the resected
tissue had been an indirect stimulus for production of
these mediators in the blood.
Proinflammatory mediator levels were hypothesized to
be higher in the hippocampus at the site of epileptogenesis.
This was true for eotaxin, IFN-γ, IL-2, IL-4, IL-12 p70, IL-
17A, TNF-α, and ICAM-1. Interestingly, Sinha et al. [15]
found that blood levels of most of these were more detect-
able in epilepsy patients than in age-matched controls.
Eotaxin (CCL11) recruits eosinophils by activating their
CCR3 receptors. CCL11 transport across the blood-brain
barrier (BBB) resulted in region-specific alterations of
eotaxin brain levels [36] and age-related increases in
humans have been implicated in cognitive decline in a
novel mouse model [37]. IFN-γ, an important activator of
macrophages and inducer of major histocompatibility class
II immune/inflammatory activities, is associated with a
number of autoinflammatory and autoimmune diseases. Its
brain levels were virtually undetectable except in 10/49
hippocampus specimens exclusively from epileptic cases.
IL-17A, also highest in the hippocampus, has synergistic
effects with IFN-γ, IL-1, and TNF-α, acting as a proinflam-
matory mediator not unlike IFN-γ [38]. TNF-α levels were
among the lowest measured in this study (Additional file 2:
Table S3B). Some variability in the convulsive effect of
TNF-α has been noted previously and its relatively reduced
levels in the entorhinal cortex may attest to this variability.
The proconvulsive effect may be concentration-dependent,
as with its role in Shigella dysenteriae-related seizures at
low concentrations and an anticonvulsive role at high
concentrations [39]. Lower picomolar concentrations may
preferentially affect the p55 receptor pathway, increasing
synaptic activity [40], and promoting epileptogenicity in
the longer term. ICAM-1 signaling is proinflammatory via
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recruitment of macrophages and leukocytes across the
BBB [22, 41]. In a mouse model of mTLE, ICAM-1
levels were locally induced in the hippocampus [22].
Neurosurgical resection of the epileptic focus signifi-
cantly reduced elevated blood levels of IL-1β, TNF-α,
and MIP-1α in mTLE patients [11]. TNF-α levels were
highest in the hippocampus, consistent with the implica-
tions of prior findings. However, brain levels of IL-1β and
MIP-1α were lower in the hippocampus compared to the
temporal cortex. Moreover, none of these mediators
showed any epilepsy-associated increases, as might
have been predicted from that study [11].
MIP-1α, IL-β, and IL-8 levels were highest in the tem-
poral cortex. MIP-1α belongs to the C–C chemokine
family (CCL3) and is involved in the recruitment and ac-
tivation of macrophages, monocytes, and neutrophils.
IL-8 (CXCL8) functions in inflammatory cell chemotaxis
and phagocytosis, as well as angiogenesis. IL-8 has also
been postulated, through NF-kB- and TNF-α-related
mechanisms, to contribute to local inflammatory mecha-
nisms in response to oxidative insults [42]. IL-β and IL-
α showed graded levels with cortical levels exceeding
those in the hippocampus. IL-1β is involved in a pleth-
ora of inflammatory activities, including the induction of
many other proinflammatory mediators; the induction of
cyclooxygenase-2 (PTGS2) by this cytokine in the CNS
is just one response to inflammation. IL-1β secreted by
hypoxic astrocytes upregulated MCP-1 and ICAM-1 levels
that are thought to play a crucial role in leukocyte recruit-
ment [43]. IL-α also mediates numerous inflammation-
related activities, including TNF induction. Both are
acute-phase cytokines that operate in the picomolar-
femtomolar range. MIP-1β, which acts as a chemoattract-
ant for natural killer cells, monocytes, and other immune
cells, was also greater in the temporal cortex than in the
entorhinal cortex.
Intriguingly, CRP levels were lower in the temporal
cortex than in the hippocampus or entorhinal cortex. As
a well-documented inflammatory biomarker, its levels
follow those of proinflammatory cytokines; this may
reflect an increased inflammatory load proximal to the
site(s) of epileptogenesis. Paradoxically, IL-10, an anti-
inflammatory cytokine, was found at higher levels in
the hippocampus than in the entorhinal cortex but not
significantly different from temporal cortical levels.
In the entorhinal cortex, IL-α and TNF-β levels were
highest, compared to the hippocampus and temporal
cortex. TNF-β (aka lymphotoxin alpha) is a highly indu-
cible, cell surface molecule that mediates a variety of in-
flammatory responses, as well as apoptotic cell death.
Findings of neuroanatomic mediator level differences
suggest brain-specific regulation; however, these might
be confounded by blood levels, with brain tissue levels
reflecting only differences in vascularization. If true, it
could be expected that more vascularized brain tissue
would regularly demonstrate higher mediator levels, but
this was not the case. Moreover, a review of the recent
literature on blood and CSF inflammatory mediator levels
indicated, at least for many mediators, that individual CSF
levels were greater than blood levels [35, 44, 45]. In com-
paring brain tissue levels in this study with consensus
blood levels from multiple studies (Additional file 2: Table
S4J, K), median brain levels exceeded median blood
levels for IP-10 (~threefold), MCP-1 (~fourfold), MIP-
1β (~threefold), IL-8 (~fivefold), IL-17A (~fourfold),
VEGF (~threefold), CRP (>tenfold), and ICAM-1 (~six-
fold). Thus, the neuroanatomic differences observed
were likely due to brain-related regulatory mechanisms
rather than contamination from the blood or CSF.
Epilepsy-related differences
Differences in inflammation-related mediators between epi-
leptic and nonepileptic subjects were further hypothesized
to suggest some significance for AED-resistant epileptogeni-
city. Caution must be taken when comparing these epilepsy
cases with nonepilepsy cases as the nonepileptic subjects
were (i) emergent neurosurgical patients and not healthy
controls, (ii) comprised only four cases, and (iii) had an age
distribution (64.5 ± 6.3) different from that of the epileptic
group (38.5 ± 1.5)(nonetheless, there was no instance where
an epilepsy-related difference could be fully explained by the
age difference). Moreover, no data were available regarding
circulating AED levels (or other medications) at the time of
surgery for these cases, so confounding influences on medi-
ator levels due to drug effects cannot be ruled out.
Eotaxin levels were lower in epilepsy specimens overall
and particularly in the entorhinal cortex. Interestingly,
phase 2 patients appeared to have higher eotaxin levels than
cases without prior electrode placement. Higher levels in
the hippocampus would suggest eotaxin is involved in both
acute (nonepileptic) and chronic (epileptic) neuroinflamma-
tion. Although IP-10 levels were also reduced in the
entorhinal cortex of epilepsy cases, this finding is suspect due
to several high nonoutlier values in the nonepileptic group.
Proinflammatory cytokines IL-1β and IL-6 were higher
in the nonepileptic cases. Both are acutely upregulated,
so it is likely the emergent conditions warranting neuro-
surgical intervention contributed to the elevations. It is
interesting to note that, for both mediators, the primary
region of increase was in the hippocampus, suggesting
that local control of these cytokines dominated, perhaps
in the early phase of neuroinflammation.
Epileptic brain exhibited higher levels of IL-12 p70
overall; most of the nonepileptic specimens had no
measurable levels. IL-12 p70 was also elevated in the
cerebral cortex of pediatric epilepsy patients, compared
to nonepileptic controls [46]. The ratio of bioactive IL-
12 p70 (p40:p35 heterodimer) to its p40 subunit
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appeared elevated both in the hippocampus and temporal
cortex, indicating a more active IL-12 in these regions
relative to the entorhinal cortex. IL-12/23 p40 levels were
much greater than IL-12 p70 levels (Additional file 2:
Table S3B), indicating that the manifestation of IL-12
bioactivity would be more dependent upon p35 subunit
availability and/or the rate of heterodimer formation. In
the periphery, IL-12 p70 stimulates T cell proliferation
and differentiation, as well as natural killer cell activation.
It also promotes induction of IFN-γ and TNF-α in T cells,
through which it may block the formation of new blood
vessels. Elevated brain IL-12 p70 in epileptics may be
associated with transient leukocyte changes observed
postictally, manifested by increased lymphocytes, neu-
trophils, NK cells, and NK-like T cells, with decreased
T cells and CD4+/CD8+ ratios [19]. These peripheral
changes were all resolved by 24 h postictally. Elevated
IL-12 p70 may also relate to alterations in specific
blood cytokines and leukocyte numbers in adult epi-
leptics that were differentially ameliorated by various
AEDs [13].
Vascular mediators CRP, ICAM-1, and VCAM-1 all
showed epilepsy-related differences. Epileptic CRP levels
were about half those of nonepileptics in the hippocampus
and temporal cortex and 63 % in the entorhinal cortex.
This was likely due to the emergent medical condition(s)
of the nonepileptic cases. Unexpectedly, epileptic ICAM-1
levels in the entorhinal cortex were about half those of
nonepileptic cases. Interestingly, blood levels of ICAM-5,
a related gene located predominantly on neural cells, were
~fivefold lower in a group of epileptic patients than in
age-matched controls [47]. ICAMs are endothelial-,
leukocyte-, and tissue-associated proteins important in
cell-cell adhesion and leukocyte extravasation [41, 48]. In
this study, ICAM-1 levels were highest in the hippocam-
pus, particularly among the epilepsy cases. Conversely,
VCAM-1 levels were much lower in the epileptic cases
across all three brain regions (11 % in the hippocampus,
23 % in the entorhinal cortex, 24 % in the temporal
cortex). Moreover, the regional VCAM-1 differences
noted in the nonepileptic cases were not apparent in
the larger group of epileptic cases. While nonepileptic
cases comprised a very small, nonage-matched sam-
ple, this might have implications for epilepsy-related
changes in hippocampal VCAM-1. Not much is
known about the contribution of human VCAM-1 to
neuroinflammation, though its levels increased acutely
in the blood and CSF after brain injuries [49, 50]. Again,
the emergent nature of the nonepileptic cases might ex-
plain these differences.
Though the epilepsy-related differences will require
further investigation to corroborate, several other notable
findings were derived from these results. Distinct regional
levels of inflammation-related mediators likely have
significance in neuroinflammatory physiology. For ex-
ample, correlations of mediator levels within and between
individual brain regions reveal the influences of intrinsic
and extrinsic controls on neuroinflammatory regulation.
These are summarized below.
Mediator-to-mediator correlations
Of the inflammation-related mediators with significant
correlation(s), 70 % were with other mediators within a
single brain region. Intraregional correlations support the
notion of local control of multiple mediators, whereas
correlations between different brain regions support more
external mechanisms. Half of the observed correlations
within a single brain region were in the temporal cortex,
suggesting greater local regulatory mechanisms, compared
to those of the hippocampus and entorhinal cortex.
Correlations of different mediators in different regions
suggested more external control mechanisms (e.g., by
diffusible factors or distributed neural cell inputs). Over
90 % of these types of correlations were between the
hippocampus and the cortical brain regions (temporal
cortex, 57 %; entorhinal cortex, 36 %). Only 7 % of
interregional correlations of different mediators were be-
tween the entorhinal and temporal cortices. Although it
cannot be known from these data in which direction con-
trols may be exerted, the preponderance of hippocampal
involvement along with their neuroanatomical relationships
suggest a focus of hippocampal control of inflammation-
related mediator levels between these regions.
Only IL-1α, IP-10, MCP-1, IL-2, VEGF, ICAM-1, and
VCAM-1 levels were correlated between different brain
regions. Of these, except for VCAM-1, tissue level differ-
ences were observed. IL-1α was greatest in the entorhinal
cortex and diminished from the temporal cortex to the
hippocampus; IP-10 was also lowest in the hippocampus,
whereas MCP-1 was greater in the hippocampus and tem-
poral cortex than in the entorhinal cortex; and IL-2, VEGF,
and ICAM-1 were higher in the hippocampus than in
both cortical regions. Thus, individual mediators showing
tissue level differences and interregional correlations
suggest the existence of common, external regulatory
mechanisms with local gain controls.
Functional implications
Systemic inflammatory cells, as well as activated intrinsic
neuroinflammatory cells, likely contribute to neurochem-
ical and neurophysiologic dysfunction in the affected brain
regions. Inflammatory mediators produced by both types
of cells can uniquely affect the brain, with little or no mani-
festation in the periphery [23]. It has been proposed that
glial cells establish a cytokine/chemokine network in the
ischemic brain—“activated microglia produce… various
types of cytokines… which activate astrocytes to synthesize
chemokines…. Chemokines in turn activate and/or recruit
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microglial cells in the injured site” [43]. Cytokines IL-1 and
TNF-α, as well as chemokines MCP-1, RANTES, and IL-8
were implicated in these networks [43].
Interestingly, the majority (110/141) of mediator-to-
mediator associations observed in this study were
accounted for by only eight mediators, namely,
eotaxin (22), ICAM-1 (17), MCP-1 (16), IL-4 (14), IL-
6 (14), IL-8 (11), MIP-1α (9), and VCAM-1 (8). This
observation implies a hierarchical dynamic in which
mediators with multiple correlations may regulate,
directly or indirectly, the levels of other mediators.
These could be one basis of neuroinflammatory func-
tional networks.
Conclusions
Both brain region-specific and epilepsy-associated dif-
ferences in inflammation-related mediator levels were
detected. The hippocampus had the majority of regional
increases. Correlations in mediator levels within and be-
tween brain regions indicated local and global regulation,
respectively. The hippocampus showed the majority of
interregional associations, suggesting a focus of inflamma-
tory control between these regions. Thus, it would be im-
portant to further characterize the range of inflammation-
related mediator levels in the normal brain and in neuro-
logic disorders like epilepsy, with recognized inflammatory
components. Finally, further characterization of differences
between epilepsies and patient responses to medications
would clarify whether AED-resistant seizures resulted from
underlying differences in the inflammatory status of the
affected brain regions.
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